|
[1] Yeaman M R, Yount N Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacolog Rev, 2003,55(1): 27-55.
[2] Mota-Meiral M, Morency H, Lavoie M C. In vivo activity of mutacin B-Ny266. J Antimicrob Chemother, 2005,56(5): 869-871.
[3] Nijnik A, Hancock R E W. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerging Health Threats J, 2009,2: e1.
[4] 黎定军, 陈武, 罗宽. 侧孢芽孢杆菌抑菌物质性质. 湖南农业大学学报(自然科学版), 2007, 33(4): 471-474. Li D J, Chen W, Luo K. On characteristics of the antibiotics secreted by Bacillus laterosporus strain 2-Q-9. J Hunan Agricultural University (Natural Sciences), 2007, 33(4): 471-474.
[5] Keymanesh K, Soltani S, Sardari S. Application of antimicrobial peptides in agriculture and food industry. World J Microbiol Biotechnol, 2009, 25(6): 933-944.
[6] Montesinos E. Antimicrobial peptides and plant disease control. FEMS Microbiol Lett, 2007,270: 1-11.
[7] Zasloff M. Antimicrobial peptides of multicellular organisms. Nature, 2002,415(6870): 389-395.
[8] Toke O. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers, 2005, 80(6):717-735.
[9] Venugopal D, Klapper D, Srouji A H, et al. Novel antimicrobial peptides that exhibit activity against select agents and other drug resistant bacteria. Bioorg Med Chem, 2010,18(14):5137-5147.
[10] Oyston P C F, Fox M A, Richards S J. Novel peptide therapeutics for treatment of infections. J Med Microbiol, 2009,58(Pt 8):977-987.
[11] Hong R W, Shchepetov M, Weiser J N, et al. Transcriptional profile of the Escherichia coli response to the antimicrobial insect peptide cecroin A. Antimicrob Agents Chemother, 2003, 47:1-6.
[12] Bell G, Gouyon P H. Arming the enemy: the evolution of resistance to self-proteins. Microbiol, 2003, 149(Pt 6):1367-1375.
[13] Perron G G, Zasloff M, Bell Graham. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci B, 2006, 273(1583):251-256.
[14] Bader M W, Sanowar S, Daley M E, et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell, 2005,122(3):461-472.
[15] Guina T, Yi E C, Wang H, et al. A PhoP-Regulated Outer Membrane Protease of Salmonella enterica Serovar Typhimurium Promotes Resistance to Alpha-Helical Antimicrobial Peptides. Bacteriol, 2000, 182(14):4077-4086.
[16] Gunn J S. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol, 2008,16(6):284-290.
[17] Li M, Cha D J, Lai Y P, et al. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol, 2007a, 66(5):1136-1147.
[18] Li M, Lai Y P, Villaruz A E, et al. Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci U S A, 2007b, 104(22): 9469-9474.
[19] Kox L F, Wosten M M, Groisman E A. A small protein that mediates the activation of a two-component system by another two-component system. EMBO J, 2000,19(8): 1861-1872.
[20] Kato A, Groisman E A. Connecting two-component regulatory systems by a protein that protects a response regulator from dephosphorylation by its cognate sensor. Genes Dev, 2004, 18(18): 2302-2313.
[21] Pietiäinen M, Gardemeister M, Mecklin M, et al. Cationic antimicrobial peptides elicit a complex stress response in Bacillus subtilis that involves ECF-type sigma factors and two-component signal transduction systems.Microbiol, 2005,151(5):1577-1592.
[22] Kovács M, Halfmann, Fedtke I, et al. A Functional dlt Operon, encoding proteins required for incorporation of D-alanine in teichoic acids in Gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae. J Bacteriol, 2006, 188(16): 5759-5805.
[23] Peschel A. How do bacteria resist human antimicrobial peptides? Trends Microbiol, 2002, 10(4): 179-186.
[24] Abachin E, Poyart C, Pellegrini E, et al. Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. Mol Microbiol, 2002, 43(1): 1-14.
[25] McBride S M, Sonenshein A L. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology, 2011,157(Pt5):1457-1465.
[26] Abi Khattar Z, Rejasse A, Destoumieux-Garzón D, et al. The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects. J Bacteriol, 2009, 191 (22) :7063-7073.
[27] Samant S, Hsu F F, Neyfakh A A, et al. The Bacillus anthracis protein MprF is required for synthesis of lysylphosphatidylalycerols and for resistance to cationic antimicrobial peptides. J Bacteriol, 2009, 191(4): 1311-1319.
[28] Ernst C M, Peschel A. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phosphorlipids. Molecul Microbiol, 2011, 80(2): 290-299.
[29] Peschel A, Jack R W, Otto M et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. Exp Med, 2001,193(9):1067-1076.
[30] Ernst C M, Staubitz P, Mishra N N, et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog, 2009,5 (11): e1000660.
[31] Moon K, Gottesman S. A PhoQ/P-regulated small RNA regulates sensitivity of Escherichia coli to antimicrobial peptides. Mol Microbiol, 2009, 74(6):1314-1330.
[32] Herrera C M, Hankins J V, Trent S. Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides. Mol Microbiol, 2010, 76(6): 1444-1460.
[33] Zhou Z M, Ribeiro A A, Lin S H, et al. Lipid A Modifications in Polymyxin-resistant Salmonella typhimurium PMRA-dependent 4-amino-4-deoxy-l-arabinose, and phosphorethanolamine incorporation. J Biol Chem, 2001, 276(46):43111-43121.
[34] Raetz C R, Reynolds C M, Trent M S, et al. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem, 2007, 76: 295-329.
[35] Campos M A, Vargas M A, Regueiro V, et al. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun, 2004, 72(12): 7107-7114.
[36] Jin T, Bokarewa M, Tarkowski A. The role of urokinase in innate immunity against Staphylococcus aureus. Microbes Infect, 2005,7(9-10): 1170-1175.
[37] Llobet E, Tomás J M, Bengoechea J A. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology, 2008, 154(Pt 12):3877-3886.
[38] Bader M W, Navarre W W, Shiau W, et al. Regulation of Salmonella typhimurium virulence gene expression by cationic antimicrobial peptides. Mol Microbiol, 2003,50(1):219-230.
[39] Sieprawska-Lupa M, Mydel P, Krawczyk K, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother, 2004, 48(12): 4673-4679
[40] Nyberg P, Rasmussen M, Björck L. Alpha-2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J Biol Chem, 2004,279(51): 52820-52823.
[41] Johansson L, Thulin P, Sendi P, et al. Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infect Immun, 2008,76(8):3399-3404.
[42] Karlsson C, Andersson M L, Collin M, et al. SufA——a novel subtilisinlike serine proteinase of Finegoldia magna. Microbiology, 2007, 153: 4208-4218.
[43] Schmidtchen A, Frick I M, Andersson E, et al. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol, 2002,46(1):157-168.
[44] Meiller T F, Hube B, Schild L, et al. A novel immune evasion strategy of Candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS One, 2009,4(4):e5039.
[45] Vincents B, Onnerfjord P, Gruca M, et al. Down-regulation of human extracellular cysteine protease inhibitors by the secreted staphylococcal cysteine proteases, staphopain A and B. J Biol Chem, 2007,388(4): 437-446.
[46] Potempa J, Pike R N. Corruption of innate immunity by bacterial proteases. J Innate Immun, 2009,1(2):70-87.
[47] Lai Y, Villaruz A E, Li M, et al. The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in Staphylococci. Mol Microbiol, 2007, 63(2):497 -506.
[48] Giuliani A, Rinaldi A C. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches.Cell Mol Life Sci,2011,68(13):2255-2266.
[49] Davis J, Davies D. Origin and evolution of antibiotic resistance. Microbiol Mol Biol Rev, 2010,74(3): 417-433.
[50] Putman M, van Veen H W, Konings W N. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev, 2000,64(4):672-693.
[51] Davidson A L, Dassa E, Orelle C, et al. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev, 2008,72(2): 317-364.
[52] Davidson A L, Maloney P C. ABC transporters: how small machines do a big job. Trends Microbiol, 2007, 15(10):448-455.
[53] Boumendjel A, Boutonnat J, Robert J. ABC transporters and multidrug resistance. New Jersey: John Wiley & Sons, 2009: 184-195.
[54] Seeger M A, van Veen H W. Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta, 2009(5), 1794: 725-737.
[55] Linton K J. Structure and function of ABC transporters. Physiol, 2007, 22(2): 122-130.
[56] Collins B, Curtis N, Cotter P D, et al. The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to Nisin, Bacitracin, and various β-Lactam Antibiotics. Antimicrob Agents Chemother, 2010,54(10):4416-4423.
[57] Dintner S, Staron, Berchtold E, et al. Coevolution of ABC transporters and two-component regulatory systems as resistance modules against antimicrobial peptides in Firmicutes Bacteria. Bacteriol, 2011, 193(15): 3851-3862.
[58] Vardy E, Arkin I T, Gottschalk K E, et al. Structural conservation in the major facilitator superfamily as revealed by comparative modeling. Prot Sci, 2004, 13(7):1832-1840.
[59] Law C J, Maloney P C, Wang D N. Ins and outs of major facilitator superfamily antiporters. Annu Rev Microbiol, 2008, 62: 289-305.
[60] Fluman N, Bibi E. Bacterial multidrug transport through the lens of the major facilityator superfamily. Biochim Biophys Acta, 2009, 1794(5): 738-747.
[61] Saier M H, Beatty J T, Goffeau A, et al. The major facilitator superfamily. Mol Mcirobiol Biotechnol, 1999,1(2): 257-279.
[62] Brogden K A, Chris Mininon K F, Cornick N, et al. Virulence mechanisms of bacterial pathogens. Third Edition. Washington: American Society for Microbiology Press, 2007. 32-33.
[63] Nikaido H. Multidrug efflux pumps of gram-negative bacteria. Bacteriol, 1996, 178(20):5853-5859.
[64] Takatsuka Y, Chen C, Nikaido H. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pumps AcrB of Escherichia coli. Proc Nat Acad Sci U S A, 2010, 107(15): 6559-6565.
[65] Murakami S. Multidrug efflux transporter, AcrB-the pumping mechanism. Curr Opin Struct Biol, 2008, 18(4): 459-465.
[66] Misra R, Bavro V N. Assembly and transport mechanism of tripartite drug efflux systems. Biochim Biophys Acta, 2009, 1794(5): 817-825.
[67] Bay D C, Rommens K L, Turner R J. Small multidrug resistance proteins: a multidrug transporter family that continues to grow. Biochim Biophys Acta, 2008, 1778(9): 1814-1838.
[68] Paulsen I T, Skurray R A, Tam R, et al. The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol Microbiol 1996, 19(6):1167-1175.
[69] Kolbusz M A, Horst R, Slotboom D J, et al. Orientation of small multidrug resistance transporter subunits in the membrane: correlateion with the positive-inside rule. Mol Biol, 2010,402: 127-138.
[70] Bay D, Turner R J. Diversity and evolution of the small multidrug resistance protein family. BMC Evolut Biol, 2009,9:140.
[71] Kuroda T, Tsuchiya. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta, 2009,1794(5): 763-768.
[72] Morita Y, Kodama K, Shiota S, et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother, 1998, 42(7): 1778-1782.
[73] Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie, 2005, 87(12): 1137-1147.
[74] Pagès J M, Amaral L. Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta, 2009,1794(5):826-833.
[75] Pagès J M, Sandrine A F, Mahamoud A, et al. Efflux pumps of gram-negative bacteria, a new target for new molecules. Curr Top Med Chem, 2010,10(18): 1848-1857.
[76] Askoura M, Mottawea W, Abujamel T, et al. Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med, 2011, 6:5870.
[77] Lubelski J, Konings W N, Driessen A J M. Distribution and physiology of ABC-type transporters contributing to multi-drug resistance in Bacteria. Microbiol Mol Biol Rev, 2007,71(3): 463-476.
[78] Ejim L, Farha M A, Falconer S B, et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol, 2011, 7(6):348-350.
[79] Hammami R, Fliss I. Current trends in antimicrobial agent research: chemo- and bioinformatics approaches. Drug Discov Today, 2010, 15(13-14): 540-546.
[80] Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Bio Rev, 2004, 68(4): 669-685.
[81] Wong H L, Chattopadhyay N, Wu X Y, et al. Naontechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev, 2010, 62(4-5): 503-517.
|
